

Neuroprotection

Part I: Drugs & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

December 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist qualifications. He received graduate training in both Europe and USA and has held academic positions in several countries. He has been involved in biotechnology/pharmaceutical industry since 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK since 2000. After his retirement from neurosurgery, he is a consultant at Jain PharmaBiotech in Basel, Switzerland.

Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. As associate editor and contributing author of MedLink Neurology (San Diego, California), he is responsible for writing and yearly updating of 160 articles for continuing education of neurologists in an electronic encyclopedia of neurology. He has also written the Textbook of Gene Therapy, which was translated into Chinese, and a book on gene therapy companies published in 2000 by John Wiley & Sons. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer, 2008; 2nd ed 2014) and "Drug Delivery to the Central Nervous System", (Springer/Humana 2010). His recent books include "Handbook of Nanomedicine" (Springer/Humana 2008, Chinese edition by Peking University Press, 2011; 3rd ed Springer 2017), "Drug-induced Neurological Disorders, 3rd ed" (Hogrefe 2011), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011), and "Applications of Biotechnology in Neurology" (Springer 2013). He has also edited "Applied Neurogenomics" (Springer 2015).

Prof. Jain has been involved in various neuroprotective strategies during his active neurosurgical career including use of hypothermia, hyperbaric oxygen and induced coma. He has a personal experience of methods of neuroprotection used in the care of patients with stroke and CNS trauma as well as during neurosurgical operations.

**December 2017 (first edition published in April 2000)
Copyright © 2017 by:**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	27
1. Introduction	31
Definitions	31
Historical development of neuroprotection	31
Neurophysiological basis of neuroprotection	32
Astrocytic glycogen-derived lactate as fuel for the brain.....	32
Gene expression in the human brain	32
Role of astrocytes in neuroprotection.....	33
Role of glymphatic system in neuroprotection.....	33
Role of sleep in neuroprotection.....	34
Role of cerebral metabolism in neuroprotection	34
Role of circadian genes in neuroprotection	34
Role of blood-brain barrier in neuroprotection.....	35
Role of the gut microbiota in development of integrity of the BBB	35
Intrinsic neuroprotective factors	35
Neuroprotective gene expression	37
<i>Upregulation of GADD34.....</i>	<i>37</i>
<i>Induction of NR4A proteins by CREB in neurons.....</i>	<i>37</i>
<i>Elevation PGC-1α for neuroprotection in PD.....</i>	<i>37</i>
Neurotrophic factors.....	38
Intrinsic nonenzymatic antioxidants	38
Activation of transcription factor Nrf2	38
Intrinsic neuroprotective proteins.....	39
<i>αB-crystallin.....</i>	<i>39</i>
<i>Excitatory amino acid transporters.....</i>	<i>39</i>
<i>Extracellular serine protease thrombin.....</i>	<i>39</i>
<i>Galanin.....</i>	<i>39</i>
<i>Neuroglobin</i>	<i>40</i>
<i>Nuclear factor I-A</i>	<i>40</i>
<i>Prion protein</i>	<i>41</i>
<i>Rai adaptor protein</i>	<i>41</i>
Stem cell factor	41
Role of the immune system in neuroprotection	41
Induction of DNA repair enzymes for neuroprotection.....	42
Microtubule-based neuroprotective response to axonal injury	43
Pathomechanisms of CNS injury as basis for neuroprotection	43
Biomarkers of neurological disorders and neuroprotection.....	44
CNS biomarker identification using proteomics	44
Brain imaging for detection of biomarkers	45
Role of neuroprotection in various neurological disorders	45
Neuroprotection and neuroregeneration.....	46
Acute versus chronic neuroprotection	46
Discovery and evaluation of neuroprotective agents	47
Neuroprotective drug discovery	47
Discovery of CNS drugs that penetrate the blood-brain barrier	47
In vitro assays for the evaluation of neuroprotective agents	48
Oxidative injury model to test neuroprotective drugs	48
Apoptosis model for designing neuroprotective drugs	48
Transgenic mouse models of neurological disorders.....	49
Evaluating effects of neuroprotective drugs on living brain slices.....	49
Role of brain imaging in neuroprotective drug discovery and development	50
<i>Positron emission tomography.....</i>	<i>50</i>
<i>Role of single photon emission computed tomography.....</i>	<i>50</i>
<i>Functional CT scanning to evaluate cerebrovascular protection</i>	<i>51</i>
<i>Magnetic resonance imaging for the evaluation of neuroprotectives.....</i>	<i>51</i>
Application of nanotechnology to neuroprotection	51
<i>Nanoparticles as neuroprotective antioxidants</i>	<i>52</i>
<i>Cadmium telluride nanoparticles prevent Aβ fibril formation</i>	<i>53</i>
Evaluation criteria for potential neuroprotective agents.....	53
2. Neuroprotective Agents	55
Classification of neuroprotective agents	55
α2 adrenoreceptor agonists	59
Dexmedetomidine.....	59
Activated protein C	60
Activity-dependent neuroprotective protein	60

Davunetide	60
Adenosine analogs.....	60
Propentofylline	61
Antidepressants.....	61
Antidepressant-induced neurogenesis.....	61
Neurogenesis induced by electroconvulsive therapy	62
Neuroprotective effect of selective serotonin reuptake inhibitors	62
Antiepileptic drugs as neuroprotectives.....	64
BIS-001.....	65
Levetiracetam	65
Phenytoin	65
Valproic acid.....	66
Antiinflammatory agents	66
Aspirin.....	66
Interleukin-1 antagonists.....	67
COX-2 inhibitors	67
<i>Nimesulide</i>	67
Gold microparticles as anti-neuroinflammatory agents.....	68
Minocycline	68
Prostaglandin receptor antagonists.....	69
Anti-apoptosis agents.....	70
Activated protein C	70
Calpain inhibitors	70
Caspase inhibitors.....	71
DNA binding drugs	71
Lithium.....	71
Melatonin.....	72
Olesoxime.....	72
Omega-3 fatty acids.....	72
<i>Docosahexaenoic acid</i>	72
Poly(ADP-ribose) polymerase inhibitors	73
Prevention of apoptosis by binding of proNGF to sortilin.....	74
Antioxidants/free radical scavengers	74
Free radical generation	74
Natural defenses against oxidative stress.....	74
Effects of oxidative damage	75
<i>Oxidative damage and aging</i>	75
<i>Neuronal damage by free radicals</i>	76
<i>Oxidative damage and neurodegenerative disorders</i>	76
Measures to control oxidative stress.....	76
<i>Categories of therapeutic antioxidants</i>	76
<i>Alpha-phenyl-tert-butyl nitron</i>	77
<i>Coenzyme Q10</i>	77
<i>Dihydroergocryptine</i>	78
<i>Flavonoids</i>	78
<i>Mitochondria-targeted antioxidants</i>	79
<i>Neuroleptics as antioxidants</i>	79
<i>Nitrones</i>	79
<i>NRF2 for augmenting neuroprotection against oxidative stress</i>	80
Translation of antioxidant neuroprotection from preclinical to clinical.....	80
Carbon monoxide and heme oxygenase.....	80
Cell transplants.....	81
Cells secreting neuroprotective substances.....	81
Stem cells.....	81
Stem cell activation for neuroprotection/regeneration by glucocorticoids.....	82
Use of neural stem cells to construct the blood brain barrier.....	82
Cytokines.....	82
Erythropoietin	82
<i>Non-erythropoietic EPO variants and mimics</i>	84
Granulocyte colony-stimulating factor.....	84
Delta-opioid receptor agonists.....	85
Delta opioid peptide-induced hibernation for neuroprotection	85
FK960	85
Gene therapy	86
Glucagon-like peptide.....	86
Glatiramer acetate.....	87
Glutamate antagonists.....	87
Neuroprotection by scavenging blood glutamate	88
N-acylethanolamines for protection against glutamatergic excitotoxicity	89
Glutamate transporters.....	89
Glutamate transporter-mediated neuroprotective effect of drugs.....	89

Neuroprotection by targeting KAI subunit of kainate receptor	90
Glycine-proline-glutamate analogs	90
Hydrogen sulfide.....	91
Hibernation induced by hydrogen sulfide.....	91
NMDA receptor ion channel complex.....	91
NMDA receptor antagonists	93
<i>NMDA NR2B subunit receptor antagonists</i>	<i>93</i>
<i>Ifenprodil.....</i>	<i>93</i>
<i>Memantine as a neuroprotective agent</i>	<i>93</i>
<i>NAALADase inhibitors</i>	<i>94</i>
<i>Gacyclidine</i>	<i>94</i>
<i>N-alkylglycines</i>	<i>94</i>
AMPA receptor modulators	94
Metabotropic glutamate receptor modulators.....	95
Cannabinoids.....	95
Dexanabinol	96
Glutathione.....	96
Heat shock proteins	97
Histone deacetylase inhibitors for neuroprotection	97
Hormones	97
Estrogen and neuroprotection.....	97
<i>Neuroprotective effect of estrogen receptor ligands.....</i>	<i>98</i>
<i>Selective estrogen receptor modulators</i>	<i>99</i>
<i>Mitochondrial mechanisms of estrogen neuroprotection</i>	<i>99</i>
Insulin	99
Ion Channel modulators	100
Calcium channel blockers.....	100
<i>Ziconotide.....</i>	<i>101</i>
Na ⁺ channel blockers.....	101
Neuroprotective potassium channel inhibitors.....	101
Kynurenine inhibitors	102
Leukocyte adhesion inhibitors	102
Modafinil.....	103
Neural regeneration protein	103
Neurite outgrowth-promoting prostaglandin compounds	104
Neuroimmunophilins.....	104
Cyclosporin-A	104
FK506	105
Rapamycin	105
Neurotrophic factors.....	105
Activity-dependent neurotrophic factor	106
Bone morphogenetic proteins	106
Brain-derived neurotrophic factor.....	106
Ciliary neurotrophic factor.....	107
Fibroblast growth factors	107
Glial cell line-derived neurotrophic factor	108
Insulin-like growth factor.....	108
Nerve growth factor	109
Neurotrophins	110
Osteogenic protein-1	110
Pigment epithelium-derived factor.....	110
Transforming growth factor-β1	110
Vascular endothelial growth factor	111
Neurotrophic factor-related neuroprotective agents	111
<i>Amitriptyline as a TrkA and TrkB receptor agonist</i>	<i>111</i>
<i>Colivelin.....</i>	<i>111</i>
<i>Gambogic amide.....</i>	<i>112</i>
<i>Inosine</i>	<i>112</i>
<i>Meteorin</i>	<i>112</i>
<i>Oxygen-regulated protein 150 kD</i>	<i>112</i>
<i>Prosaptide.....</i>	<i>113</i>
<i>Siagoside.....</i>	<i>113</i>
<i>Small molecule activators of the Trk receptors.....</i>	<i>113</i>
Nicotine and nicotinic receptor agonists	114
<i>Neuroprotective effect of galantamine mediated via α7nAChRs</i>	<i>114</i>
<i>Galantamine-induced Aβ clearance via α7nAChRs</i>	<i>115</i>
Nitric oxide-based neuroprotection	115
Nitric oxide synthase inhibitors	115
Nitric oxide mimetics	116
Nitric oxide donating derivatives	116
Nootropics	116

<i>Piracetam</i>	117
Nutraceuticals and naturally-derived compounds	117
Cinnamon	117
Coffee	118
Creatine.....	118
Curcumin/curry	119
<i>Mechanism of neuroprotective effect of curcumin</i>	119
Flavonoids	119
Glyceryltriacetate.....	120
Green tea	120
Herbal preparations.....	120
<i>Flavonoid wogonin</i>	120
<i>Ginseng</i>	121
Nicotinamide	121
Punicalagin from pomegranate	121
Resveratrol	121
Osmotic diuretics	122
Mannitol	122
Osteopontin	123
Oxygen therapeutics	123
Oxygen carriers	123
Hemoglobin-based oxygen carriers.....	124
Perfluorocarbons as oxygen carriers	124
Hyperbaric oxygen therapy	125
P7C3 compounds	125
Peptides	126
C3-derived peptide for neuroprotection and neuroregeneration	126
Corticotropin-releasing hormone.....	126
Thyrotropin-releasing hormone.....	126
Vasoactive intestinal peptide	127
Pharmacological preconditioning	127
PPARs as drug targets for neuroprotection	128
Proteins	128
Amyloid precursor protein	128
Protein kinase C activators.....	129
Riluzole	129
Role of RNA interference in neuroprotection	129
Role of miRNA in neuroprotection.....	130
Sigma receptor agonists as neuroprotective agents	130
SIRT group of proteins	131
Statins	131
Steroids	132
Dehydroepiandrosterone.....	132
HF0220	133
Sulforaphane	133
Tauroursodeoxycholic acid	133
Tetanus toxin as a neuroprotective agent	134
Thrombolytic agents as neuroprotective agents	134
Uncoupling protein 2	134
Vaccines as neuroprotectives	135
Vitamins as neuroprotective agents	135
Vitamin B12	135
Vitamin D	136
Non-pharmacological approaches to neuroprotection	136
Caloric restriction.....	136
Cerebral exercise	136
<i>Bilingualism for prevention of decline of mental function</i>	136
Electrical fields for improvement of cerebral function in neurodegeneration	137
Environmental enrichment	137
Hypothermia	138
<i>Limitations of hypothermia</i>	138
<i>Hypothermic neuroprotection in hypoxia-ischemia</i>	139
Ketogenic diet	139
Mediterranean diet.....	140
Nonpharmacological preconditioning for neuroprotection.....	140
Physical exercise.....	140
Suspended animation and neuroprotection	141
Transcranial magnetic stimulation	142
3. Neuroprotection in Cerebrovascular Disease	143
Introduction	143

Pathophysiology of cerebral ischemia.....	144
Calcium overload	144
Ion channel dysfunction in stroke.....	145
Role of oxygen free radicals in cerebral ischemia	145
Role of nitric oxide in cerebral ischemia	145
Glutamate as a biomarker of stroke	145
Cerebral edema in stroke.....	146
Gene expression in response to cerebral ischemia.....	146
Induction of heat shock proteins in stroke.....	146
Role of cytokines and adhesion molecules in stroke.....	147
<i>Tumor necrosis factor-α</i>	147
<i>Interleukin-1 and IL-6</i>	147
<i>Adhesion molecules</i>	147
DNA damage and repair in cerebral ischemia.....	147
Role of neurotrophic factors in stroke	148
<i>Problems requiring investigation of the role of NTFs in stroke</i>	148
Role of Poly(ADP-ribose) polymerase (PARP) gene	149
Role of protease-activated receptor 1	149
Reperfusion injury after cerebral ischemia	149
Neuroprotection according to zones in cerebral infarction.....	149
Zone of ischemic infarction.....	149
Penumbra	150
Current management of stroke	151
Neuroprotection in stenosis of intracranial arteries	151
Neuroprotection in stroke with intracerebral hemorrhage	151
Neuroprotection in cavernous cerebrovascular malformations	152
Neuroprotective strategies for ischemic stroke in patients with dementia	152
Neuroprotection in transient ischemic attacks.....	153
Secondary prevention of stroke	153
Neuroprotective therapies for stroke	153
Pharmacologic neuroprotective agents for stroke.....	154
α B-crystallin as a neuroprotectant in stroke	154
Acid-sensing ion channel blockers	155
AMPA receptor antagonists as neuroprotectives for stroke.....	155
<i>Zonampanel</i>	155
Antiapoptotic neuroprotectives	155
<i>NIM811</i>	155
<i>Creatine as neuroprotective in stroke</i>	156
<i>Lithium as a neuroprotective in stroke</i>	156
<i>TUDCA as a neuroprotective in stroke</i>	156
Antiepileptic drugs as neuroprotectives in stroke.....	157
<i>Tiagabine</i>	157
<i>Topiramate</i>	157
<i>Zonisamide</i>	157
Anti-HMGB1 monoclonal antibody	157
Antioxidant approaches	158
<i>Carnosine as a neuroprotective in stroke</i>	158
<i>Dehydroascorbic acid</i>	158
<i>Tocotrienols</i>	159
<i>Uric acid</i>	160
Antiglutamate compounds.....	160
<i>MRZ 2/576</i>	160
<i>L-Phenylalanine</i>	160
Arimocloamol for stroke	160
Cardiac glycosides as neuroprotectives in stroke.....	161
Clenbuterol	161
Coagulation inhibitors as neuroprotectives	161
<i>Heparin and enoxaparin</i>	161
<i>Warfarin vs dabigatran</i>	162
<i>Apixaban</i>	162
Cox-2 inhibitors for ischemic stroke.....	162
Curcumin as a neuroprotectant in stroke.....	162
Docosahexaenoic acid for ischemic stroke	163
Ephrin-A5 blockers.....	163
Estrogen for stroke	163
Extendin-4	165
Flavones for neuroprotection in stroke.....	165
<i>Epicatechin</i>	165
<i>Isorhamnetin</i>	165
Granulocyte-macrophage colony-stimulating factor for cerebral ischemia.....	166
Hamartin induction by cerebral ischemia as a basis for neuroprotection	166

Histone deacetylase inhibitors for neuroprotection in stroke	166
Histamine H ₂ -receptor modulation.....	167
Inosine for stroke	167
Insulin-like growth factor-I.....	167
Intravenous immunoglobulin as neuroprotective in stroke.....	167
Ischemic preconditioning for neuroprotection in stroke	168
Ketone bodies for neuroprotection in stroke	169
Magnesium	169
Mineralocorticoid receptor blockade for neuroprotection.....	169
miR-223 and neuroprotection in stroke.....	169
Multifunctional neuroprotective agents.....	170
NA-1 as neuroprotective against ischemic stroke	170
Nasal delivery of neuroprotective agents in stroke	170
Neuroserpin as a neuroprotective in stroke	170
N-2-mercaptopropionyl glycine	171
NeuroAiD	171
Neurotrophic factors as neuroprotectives for stroke.....	172
<i>Brain-derived neurotrophic factor</i>	172
<i>Fibroblast growth factor</i>	172
<i>G-CSF</i>	172
<i>Glial cell line-derived neurotrophic factor</i>	173
<i>Insulin-like growth factor-1</i>	173
<i>Neuregulin-1</i>	173
NO-based strategies for neuroprotection in cerebral ischemia	173
NOX-4 inhibitors for neuroprotection in stroke.....	174
Omega-3 fatty acids for neuroprotection after cerebral ischemia-hypoxia.....	174
Pannexin channel blockers for neuroprotection in stroke	175
Perlecan domain V	175
Peroxisome proliferator-activated receptor- γ agonists	175
PGE ₂ EP2 receptor activation	175
Pioglitazone for reduction of stroke risk	176
Progesterone.....	176
Propofol as neuroprotective in stroke.....	176
Proteoglycan-degrading enzymes.....	176
Proteasome inhibitors.....	177
Statins for prevention and neuroprotection in stroke	177
Sildenafil	178
Src receptor blockade.....	178
Stroke vaccine.....	178
SUN N4057	179
Thrombosis inhibitors	179
<i>Aspirin</i>	179
<i>Clopidogrel</i>	180
<i>Dipyridamole</i>	180
<i>Ticagrelor</i>	180
Vitamin E for neuroprotection in stroke.....	180
Neuroprotection in ischemia-reperfusion injury	181
Aminoguanidine.....	181
Dexmedetomidine	181
Methylene blue for neuroprotection in ischemia-reperfusion injury	182
Miscellaneous agents for neuroprotection in reperfusion injury.....	182
Neuroprotection by treatment of cerebrovascular malformations.....	182
Cerebral cavernous malformations	182
Prevention of hemorrhage following ischemic stroke	183
Non-pharmacological neuroprotective therapies for stroke	183
Hypothermia for neuroprotection in acute stroke.....	183
Hyperbaric oxygen therapy for neuroprotection in acute stroke.....	184
Hypothermia combination with other neuroprotective strategies	184
Infrared laser therapy for ischemic stroke	185
Preconditioning for neuroprotection against cerebral ischemia	185
Neurosurgical procedures for stroke.....	186
Neurosurgical procedures for neuroprotection in acute stroke	186
Neurosurgical procedures for chronic cerebral ischemia	188
Neurostimulation of sphenopalatine ganglion.....	188
Stent versus surgery for asymptomatic carotid stenosis.....	189
Neurorehabilitation in relation to neuroprotection in stroke.....	189
Protective effect of physical activity on stroke in the elderly	189
Biological therapies for stroke	189
Cell therapy for stroke.....	189
<i>Stem cell transplant for stroke</i>	190
<i>Immortalized cell grafts for stroke</i>	190

<i>Stimulation of intrinsic stem cells for repair of brain in stroke</i>	190
Gene therapy for neuroprotection in cerebrovascular disease	191
Regulation of microRNAs for neuroprotection in cerebral ischemia	193
RNAi-based therapy for neuroprotection in stroke	193
Vaccines for neuroprotection in stroke	193
Neuroprotective therapies for cerebral ischemia: clinical trials	194
Albumin	195
Free radical scavengers	195
DP-b99	196
Mildronate	196
Minocycline for neuroprotection in stroke	197
Perindopril	197
Failed clinical trials of neuroprotection in stroke	197
<i>Ancrod</i>	199
<i>Aptiganel</i>	199
<i>Cerovive</i>	199
<i>Citicoline</i>	200
<i>Desmoteplase</i>	201
<i>Erythropoietin as a neuroprotective in stroke</i>	202
<i>SPD 502</i>	202
<i>Tirilazad mesylate</i>	203
<i>Selfotel</i>	203
<i>Lubeluzole</i>	203
<i>Nalmefene</i>	204
<i>Gavestinel</i>	204
<i>Nimodipine</i>	204
<i>Sipatrigine</i>	204
<i>Causes of failure of stroke trials</i>	205
Measures for prevention of failures in stroke trials	206
Design of acute stroke trial to facilitate drug approval	208
The ideal neuroprotective agent for stroke	208
Future of neuroprotection in stroke	209

4. Neuroprotection in Traumatic Brain Injury	211
Introduction	211
Cerebral hypoxia/ischemia as a complication of trauma	211
Epidemiology of TBI	211
TBI in the military	212
Pathophysiology of TBI	212
Immediate damage following TBI	213
Cerebral edema following TBI	213
Neurometabolic cascade after TBI	214
Delayed damage following TBI	214
Mechanism of axonal damage after TBI	215
Role of neuroinflammation in TBI	215
BBB damage after TBI	215
Molecular events following TBI	216
Chronic traumatic encephalopathy	216
Neurocognitive sequelae of TBI	218
Changes in neurotrophic factors following TBI	218
Changes in neurotransmitters following TBI	218
Proteomics of TBI	219
Genetic influences on outcome following TBI	219
Management of TBI	220
Management during acute phase of head injury	220
<i>Control of intracranial pressure and cerebral edema</i>	220
<i>Corticosteroids</i>	221
<i>Decompressive craniectomy</i>	222
Neuroprotection in TBI	222
Amantadine	223
Antioxidants	224
Barbiturates	224
β - and γ -secretase inhibitors	224
Beta blockers	224
Bradykinin B ₂ antagonists	225
Cell cycle inhibitors for TBI	225
COX-2 inhibitors for neuroprotection in TBI	225
Cyclosporin for neuroprotection in TBI	226
Dexanabinol for TBI	226
Erythropoietin for neuroprotection in TBI	226
Gold implants for neuroprotection in focal TBI	227

Histone deacetylase inhibitors for neuroprotection in TBI	227
KN 38-7271	227
Levosimendan	227
Magnesium sulfate	228
Minocycline for TBI.....	228
Multipotential neuroprotective agents for TBI	228
Nutritional approaches to neuroprotection in TBI.....	228
<i>Branched chain amino acids to ameliorate cognitive impairment in TBI</i>	229
<i>Creatine for neuroprotection in TBI</i>	229
<i>Nicotinamide for neuroprotection in TBI</i>	230
<i>Omega 3 fatty acids as neuroprotectives in TBI</i>	230
Neurotrophic factors for TBI	230
Neurosteroids as neuroprotective agents for TBI.....	231
NMDA receptor antagonists	232
<i>Neuroprotection in TBI against glutamate-induced excitotoxicity</i>	232
<i>NP-1</i>	233
Nogo-A inhibitor	233
Oxygen carriers for TBI.....	233
Polyethylene glycol for neuroprotection in TBI	234
Propofol for neuroprotection in TBI.....	234
Rapamycin as neuroprotective in TBI.....	234
Simvastatin as neuroprotective in TBI	235
Thyrotropin-releasing hormone analogs	235
Traxoprodil	235
Biological approaches to neuroprotection in TBI	236
Antisense approaches to TBI	236
Cell therapy for TBI.....	236
Gene therapy for TBI.....	236
Vaccines for TBI.....	237
Non-pharmaceutical approaches to neuroprotection in TBI	237
Deep brain stimulation for TBI.....	237
Hyperbaric oxygen therapy for TBI.....	237
Hypothermia	238
Reduction of microglial migration after TBI.....	238
Vacuum for mechanical tissue resuscitation in TBI	238
Prophylactic neuroprotection against TBI.....	238
Role of helmets in protection against TBI	239
Role of physical exercise in protection against TBI	239
Neuroprotection against late sequelae of TBI.....	239
Antiepileptic drugs for prevention of seizures and neuroprotection	239
Neuroprotection during rehabilitation phase of TBI.....	240
Neuroregeneration following TBI	240
<i>Intrinsic factors that influence regeneration following TBI</i>	240
<i>Causes of lack of regeneration following TBI</i>	241
<i>Approaches to regeneration of the brain following TBI</i>	241
Clinical trials of neuroprotective agents in TBI	242
Ongoing clinical trials in TBI	242
Failed clinical trials in TBI.....	243
<i>Differences between clinical trials and studies in animal models of TBI</i>	244
<i>Subgroup analysis</i>	245
<i>Improving the clinical trial design</i>	245
<i>Clinical trials combining multiple treatment strategies</i>	245
<i>Shortening the trial time</i>	245
Conclusions and future prospects of neuroprotection in TBI.....	246
5. Neuroprotection in Spinal Cord Injury	247
Introduction	247
Pathophysiology of SCI.....	247
<i>Secondary mechanisms of SCI</i>	248
<i>Neurotrophic factor changes in SCI</i>	249
Management of SCI	250
Pharmacological neuroprotective agents for SCI	251
4-aminopyridine	251
Antibodies as neurite growth inhibitors in SCI.....	251
Antiexcitotoxic agents	251
<i>Gacyclidine</i>	251
<i>GM-1 ganglioside</i>	252
Bacterial enzyme chondroitinase ABC	252
Docosahexaenoic acid as neuroprotective in SCI.....	252
Erythropoietin as a neuroprotective in SCI	253
Free radical scavengers for neuroprotection in SCI.....	253

GYKI 52466	253
Immunosuppressants as neuroprotectants in SCI.....	253
Interleukin-10 for neuroprotection in SCI.....	254
Matrix metalloproteinase inhibitors for SCI.....	254
Methylprednisolone	254
Minocycline as neuroprotective in SCI.....	255
Modulation of macrophage responses for neuroprotection after SCI.....	255
Neurotrophic factors for neuroprotection after SCI	256
<i>Promotion of regeneration of neurons in SCI</i>	<i>256</i>
Rho pathway and Rho antagonists in SCI.....	257
Selenium as a neuroprotective for SCI.....	257
Sialidase for enhancing recovery after SCI	257
Targeting the inflammatory response for neuroprotection in SCI	258
Uric acid as neuroprotective in SCI.....	258
Non-pharmacological approaches to SCI	258
Hyperbaric oxygen therapy	258
Hypothermia for SCI	258
Cell therapy for SCI	259
Autoimmune T cells against CNS myelin-associated peptide	259
Fetal neural grafts for SCI.....	259
Olfactory-ensheathing cells for SCI	259
Oligodendrocyte precursor cells for treatment of SCI.....	260
Schwann cell transplants for SCI.....	260
Transplantation of glial cells for SCI	260
Stem cells for SCI	260
<i>Bone marrow stem cells for SCI.....</i>	<i>261</i>
<i>Embryonic stem cells for SCI.....</i>	<i>261</i>
<i>Transplantation of induced pluripotent stem cells in SCI</i>	<i>261</i>
<i>Transplantation of MSCs for SCI</i>	<i>262</i>
<i>Transplantation of NSCs for SCI.....</i>	<i>262</i>
<i>Transdifferentiation of stem cells into cholinergic neurons for SCI</i>	<i>263</i>
Gene therapy for SCI	263
Combined approaches to spinal cord injury	264
Discovery of new targets for neuroprotective therapies in SCI.....	265
Clinical trials in SCI.....	265

6. Neuroprotection in Neurodegenerative Disorders..... 267

Introduction	267
Pathomechanism of neurodegeneration	267
Aging and neurodegeneration.....	267
α -synuclein in neurodegeneration and neuroprotection	268
Dysregulation of cyclin-dependent kinase 5	268
Exosomes in CNS neurodegeneration and neuroregeneration.....	268
Genomics of neurodegenerative diseases	269
Impairment of neural transport in neurodegenerative disorders	269
Lack of neurotrophic factors	269
Neuroinflammation in neurodegenerative disorders	270
Neurodegeneration associated with protein misfolding	270
<i>Modulation of neurodegeneration by molecular chaperones</i>	<i>270</i>
<i>Intrabodies targeting protein misfolding in neurodegeneration.....</i>	<i>271</i>
<i>Targeting proteins aggregation to prevent amyloid formation</i>	<i>271</i>
<i>Tau and neurodegeneration.....</i>	<i>271</i>
Role of apoptosis in neurodegenerative disorders.....	272
Role of glia in neurodegeneration.....	272
Role of metals in neurodegeneration	272
Spread of neurodegeneration	273
TDP-43 proteinopathy and neurodegenerative diseases	273
Viral infections and neurodegeneration	273
<i>AIDS and the nervous system</i>	<i>273</i>
<i>Avian influenza as cause of neurodegeneration</i>	<i>274</i>
Neurodegenerative disorders with dementia	275
Dementia with Lewy bodies.....	275
Pick disease	276
<i>Progressive supranuclear palsy.....</i>	<i>276</i>
Genetic disorders with neurodegeneration	277
Batten disease.....	277
<i>Cell and gene therapies</i>	<i>277</i>
<i>Cerliponase alfa</i>	<i>278</i>
Familial dysautonomia	278
Friedrich ataxia.....	278
<i>Pathomechanism of FA</i>	<i>278</i>

<i>Neuroprotection in FA</i>	279
Leigh syndrome	279
Niemann-Pick type C disease.....	280
Spinal and bulbar muscular atrophy	280
<i>Spinal muscular atrophy</i>	281
Creutzfeldt-Jakob disease	282
Neuroprotection in Creutzfeldt-Jakob disease	282
<i>Pharmacological neuroprotectants against CJD</i>	283
<i>Innovative approaches to neuroprotection in CJD and future prospects</i>	284
Approaches to neuroprotection in neurodegenerative disorders	284
Glutamate-based therapies for neurodegenerative disorders	285
Histone deacetylase inhibitors for neurodegenerative disorders.....	285
Iron chelation for neuroprotection.....	285
Mitochondria permeability transition pore complex and neuroprotection.....	286
Modulation of proteostasis in neurodegenerative disorders	286

7. Neuroprotection in Parkinson Disease	287
Introduction	287
Epidemiology of Parkinson's disease	287
Pathophysiology of Parkinson's disease	287
Alteration of dopamine homeostasis	288
Apoptosis.....	288
Asynchronous neuronal activity	288
Disruption of iron homeostasis.....	289
Excitotoxicity.....	289
Genetic factors in PD	289
Oxidative stress.....	290
Role of neurotrophic factors	291
Role of misfolding proteins.....	291
Synaptic vesicle glycoprotein 2C disruption in PD.....	292
Neuroprotective strategies for PD based on pathomechanism	292
A genetic animal model of PD for testing neuroprotective strategies	293
Aldehyde dehydrogenase 1 protects nigrostriatal dopaminergic neurons	294
RNAi screening to identify neuroprotective genes in a PD model	294
Strategies to stop aggregation of α -synuclein	294
Management of Parkinson's disease	295
Limitation of conventionally administered dopamine therapy	296
Neuroprotective therapy in PD	297
Neuroprotective effect of currently used drugs for PD	297
Pramipexole	297
Rasagiline mesylate	298
Ropinirole	299
Rivastigmine for treatment of dementia and falls associated with PD	299
Selegiline.....	299
Non-pharmacological strategies for neuroprotection in PD	300
Deep brain stimulation for PD.....	300
Effect of exercise and environmental enrichment on PD	301
Low-calorie diet in PD.....	301
Development of neuroprotective therapies for PD	301
2B3-201 for targeted delivery of methylprednisolone.....	302
9-methyl- β -carboline.....	302
Adenosine A ₂ receptor antagonists	302
Antiapoptotic strategies for PD	303
ATP13A2 activation	303
Augmenting CNS glucocerebrosidase activity.....	303
β 2-Adrenoreceptor agonists	304
Calcium channel blockers for PD	304
Cell therapies for PD.....	304
<i>Stem cells for PD</i>	304
<i>Activation of endogenous stem cells and neural precursors</i>	305
Cogane.....	306
Creatine and minocycline	306
Conserved dopamine neurotrophic factor for PD.....	306
Doxycycline as a neuroprotectant in PD.....	307
Free radical scavengers for neuroprotection in Parkinson's disease	307
<i>Antioxidants</i>	307
<i>Diapocynin</i>	307
<i>Tea extracts as neuroprotectives</i>	308
Gene therapy for PD.....	308
<i>Implantation of genetically engineered cells</i>	309
<i>Gene therapy using GDNF and neurturin</i>	309

<i>Glutamic acid decarboxylase gene therapy</i>	310
<i>Parkin gene therapy</i>	310
<i>Concluding remarks about gene therapy for PD</i>	311
Heat shock protein 70	311
Liver X receptor β agonists.....	311
Melatonin as a neuroprotectant in PD	312
Nicotine as a neuroprotective in PD	312
Nilotinib for PD	312
Neuroprotective effect of leucine-rich repeat kinase-2 inhibitors	313
Neuroprotective effect of DJ-1 protein	313
Neurotrophic factors.....	313
<i>Basic fibroblast growth factor for PD</i>	314
<i>BDNF for PD</i>	314
<i>GDNF for PD</i>	314
<i>MANF for PD</i>	315
<i>Neurturin for PD</i>	315
<i>Platelet derived growth factor</i>	315
<i>Clinical trials with NTFs</i>	316
Nrf2-mediated neuroprotection in PD.....	316
Nuclear receptor-related 1:Retinoid X receptor α activation	316
Omega-3 polyunsaturated fatty acids	316
RAB3B overexpression.....	317
RNAi therapy for PD	317
Safinamide.....	317
Sirtuin 2 inhibitors for neuroprotection in PD	318
Squalamine and PD	318
Statins and PD.....	319
Targeting Bax.....	319
Vitamin D for neuroprotection in PD	319
Vaccine for PD	320
Clinical trials of neuroprotection in Parkinson's disease	320
Evaluation of neuroprotective therapies for PD	322
Current status and future challenges for neuroprotection in PD	323

8. Neuroprotection in Alzheimer Disease	325
Introduction	325
Pathomechanism of Alzheimer's disease	325
Role of glutamate transport dysfunction in AD	326
Role of neurotrophic factors in the pathomechanism of AD	326
Management of Alzheimer's disease	326
Neuroprotection in Alzheimer's disease.....	327
Inhibition of Aβ formation and aggregation.....	328
AN-1792	328
Clioquinol.....	329
Colostrinin	329
FKBP52 for neuroprotection from Cu toxicity in AD.....	330
Monoclonal antibody m266.....	330
Phenserine	330
Secretase inhibitors.....	331
Inhibition of neuroinflammation	331
Etanercept	331
Neurotrophic factors for neuroprotection in AD	332
AL-108	332
NGF gene therapy	332
Small molecule compounds binding to neurotrophin receptor p75NTR.....	333
Targeting plasminogen activator inhibitor type-1 gene.....	334
Estrogen and AD	334
Antioxidants	335
NSAIDS	335
Melatonin for AD	335
Memantine.....	335
Dimebon	336
Cerebrolysin	337
Curcumin as a neuroprotectant in Alzheimer disease	337
Ginko biloba.....	337
Tetrahydrocannabinol for neuroprotection in AD	338
Ladostigil tartrate.....	339
Phosphodiesterase inhibitors as neuroprotectives.....	339
PPAR-γ agonists	339
Role of statins in reducing the risk of AD	340
Combined therapeutic approaches to AD	340

Clinical trials in AD.....	340
Future prospects of neuroprotection in AD	349
Mild cognitive impairment	349
Relation of MCI to AD	350
Neuroprotection in MCI	350
9. Neuroprotection in Huntington Disease	353
Introduction	353
Pathophysiology of HD.....	353
Management of Huntington's disease	355
Neuroprotection in Huntington's disease	355
Antipsychotic D ₂ and 5-HT _{1A} antagonists	356
Caspase inhibitors.....	356
Clioquinol for HD.....	357
Creatine for stabilizing bioenergetic defects.....	357
Cysteamine.....	357
Drugs that block inappropriate calcium release from neurons	357
Enhancing protease activity for clearance of mHtt	358
Eicosapentaenoic acid.....	358
Free radical scavengers	358
Histone deacetylase inhibitors	359
Inhibitors of polyglutamine aggregation HD.....	359
Metal-protein attenuating compounds.....	360
Pridopidine.....	360
RRAS signaling pathway inhibition.....	360
Simvastatin as a neuroprotective in HD	361
Single chain Fv antibodies.....	361
SIRT1 activators for neuroprotection in HD	361
SIRT2 inhibitors for neuroprotection in HD	362
Synaptic activation of NMDA receptors.....	362
Targeting mutant huntingtin protein.....	362
Tetrabenazine	363
Combinatorial therapy and targeting multiple pathways in HD	363
Cell therapy for HD	363
<i>Cell transplants for HD.....</i>	<i>363</i>
<i>Stem cell-based therapy for HD</i>	<i>364</i>
Neurotrophic factors and gene therapy	365
RNAi and antisense therapies for Huntington's disease	365
10. Neuroprotection in Amyotrophic Lateral Sclerosis	367
Introduction	367
Pathophysiology of ALS	367
Neuroprotective therapies for ALS.....	372
Activated protein C	373
AEOL 10150	373
AIMSPRO	373
Anakinra.....	374
Antisense therapy	374
Arimocloamol for ALS.....	374
Ceftriaxone for ALS	375
Coenzyme Q10 for ALS	375
COX-2 inhibitors for ALS	375
Creatine for ALS	376
Dexpramipexole.....	376
Diallyl trisulfide.....	376
Edaravone for ALS	377
Erythropoietin for ALS	377
Gene therapy for ALS	377
Glatiramer acetate	378
GM602	378
Insulin-like growth factor.....	378
Ketogenic diet for neuroprotection in ALS.....	379
Lenalidomide.....	379
Lithium for neuroprotection in ALS	380
Masitinib	380
Melatonin for ALS.....	380
Methylcobalamin.....	381
Minocycline for ALS	381
Olesoxime as neuroprotective for ALS.....	381
ONO-2506 for ALS	381
Riluzole	382

RNAi-based therapy for ALS	382
Sodium phenylbutyrate.....	382
Stem cell therapy.....	383
<i>Clinical applications</i>	383
<i>Stem cell-based drug discovery for ALS</i>	383
<i>Suppressors of mTDP-43 toxicity</i>	384
Talampanel	384
Tamoxifen.....	385
Vaccination for ALS caused by SOD1 mutations	385
Vascular endothelial growth factor for ALS	385
Vitamin E for ALS.....	386
Clinical trials of neuroprotective therapies for ALS	386
Concluding remarks and future prospects.....	389

11. Neuroprotection in Miscellaneous Neurological Disorders 391

Introduction	391
Neuroprotection in synaptopathies.....	391
Neuroprotection in ASD	392
Neuroprotection in fragile X syndrome	392
Neuroprotection in dementia	392
Age-related dementia	392
<i>Aging brain and oxidative stress</i>	393
<i>Enhancing endogenous neurotrophic support of the aging brain</i>	393
<i>Hsp70 and age-related neurodegeneration</i>	394
<i>Pharmacological approaches for treatment of age-related dementia</i>	394
<i>Physical exercise to prevent decline of mental function with aging</i>	395
Vascular dementia	395
<i>Prediction of dementia in persons with vascular risk factors</i>	396
<i>Management of subcortical vascular dementia</i>	396
Dementia with Lewy bodies.....	397
Neuroprotection in AIDS dementia	397
Multiple system atrophy	398
Epilepsy	399
Mechanisms of neuronal damage in epilepsy	399
Strategies for neuroprotection in epilepsy	400
AEDs and neuroprotection.....	401
Cell therapy for neuroprotection in epilepsy.....	402
<i>Cell therapy of posttraumatic epilepsy</i>	403
<i>Cell therapy for temporal lobe epilepsy</i>	403
<i>Cell therapy for pharmacoresistant epilepsies</i>	403
Gene therapy for neuroprotection in epilepsy	404
Hyaluronan-based preservation of brain ECS volume	405
Hypothermia for neuroprotection in status epilepticus.....	405
Ketogenic diet for prevention of seizures.....	405
miR-211 as an attenuator of cholinergic-mediated seizures	405
Multiple sclerosis	406
Introduction	406
Epidemiology of multiple sclerosis	406
Pathophysiology	406
Current management of multiple sclerosis.....	407
Specific therapies for MS based on pathomechanism	408
Neuroprotection in multiple sclerosis	408
Clinical trials of neuroprotective therapies for MS.....	410
Neuroprotection by control of progressive forms of multiple sclerosis	411
Neuroprotection by controlling autoimmune inflammation in the brain	411
Neuroprotection by sealing the BBB with imatinib	411
TRPM4 cation channel blockers	412
Remyelination for neuroprotection in multiple sclerosis	412
Agents for neuroprotection in multiple sclerosis	412
<i>Angiotensin-II inhibitors</i>	412
<i>Antigliutamate agents</i>	413
<i>Antioxidants for neuroprotection in MS</i>	413
<i>Antisense and RNAi approaches to MS</i>	413
<i>B cell depletion therapy</i>	413
<i>Cell therapy for multiple sclerosis</i>	414
<i>Cannabinoids for neuroprotection in MS</i>	417
<i>Cladribine</i>	417
<i>Curcumin as a neuroprotectant in multiple sclerosis</i>	417
<i>Cytokine-directed therapies in MS</i>	418
<i>Dalfampridine in MS</i>	418
<i>Dimethyl fumarate</i>	418

<i>DNA vaccine for MS</i>	419
<i>Erythropoietin as a neuroprotective in MS</i>	419
<i>Fingolimod</i>	419
<i>Fusokine composed of GM-CSF and IL-15 for immune suppression</i>	420
<i>Gene therapy for MS</i>	420
<i>Ibudilast for MS</i>	421
<i>Iron chelators</i>	421
<i>IVIg for MS</i>	421
<i>Kinase inhibitors</i>	422
<i>Laquinimod</i>	422
<i>Melatonin for MS</i>	422
<i>Minocycline for MS</i>	422
<i>Monoclonal antibodies for MS</i>	423
<i>Natalizumab</i>	424
<i>Natural human antibodies for repair of myelin</i>	424
<i>Neurotrophic factors for multiple sclerosis</i>	425
<i>Nimodipine</i>	426
<i>Oral immunomodulatory agents for MS</i>	426
<i>Protein kinase Cβ as a therapeutic target for stabilizing BBB in MS</i>	426
<i>Recombinant T-cell ligands</i>	426
<i>Statins for MS</i>	427
<i>Teriflunomide</i>	427
<i>Tolerance-directed immunotherapy for MS</i>	427
Concluding remarks and future prospects for neuroprotection in MS	428
Neuroprotection in anti-NMDA receptor encephalitis	429
Neuroprotection in transverse myelitis	429
Neuroprotection in decompression sickness	429
Neuroprotection in victims of drowning	430
Neuroprotection in CSF circulatory disorders	431
Neuroprotection in hydrocephalus	431
Neuroprotection in normal pressure hydrocephalus	431
Neuroprotection in infections of the CNS	432
Neuroprotection in bacterial meningitis	432
<i>Mechanism of neural injury in bacterial meningitis</i>	432
<i>Strategies for neuroprotection</i>	433
Neuroprotection in cryptococcal meningitis.....	433
Neuroprotective approach to rabies.....	434
Neuroprotection in cerebral malaria.....	434
Neuroprotection in complications of systemic disorders	434
Neurological complications of cardiovascular disorders.....	434
<i>Neuroprotection after myocardial infarction</i>	434
<i>Neuroprotection in hypertensive encephalopathy</i>	435
<i>Management of hypertension to prevent dementia</i>	435
Neuroprotection in complications of diabetes	436
<i>Neuroprotection in hypoglycemic coma</i>	436
<i>Neuroprotection in diabetic retinopathy</i>	437
Neurological complications of liver disorders.....	437
<i>Hepatic encephalopathy</i>	437
<i>Bilirubin encephalopathy</i>	438
Neuroprotection in neurological complications of renal disease.	439
Neuroprotection in toxic encephalopathies	440
Encephalopathy due to organophosphorus poisoning	440
Neuroprotection against chemotherapy-induced brain damage	440
Neuroprotection against alcohol	441
<i>Alcoholic neurologic disorders</i>	441
<i>Fetal alcohol syndrome</i>	441
<i>Pathogenesis of alcohol-induced damage to the nervous system</i>	442
<i>Neuroprotection against neurotoxicity of alcohol</i>	442
Neuroprotection against exposure to therapeutic radiation	442
Neuroprotection against radiation encephalopathy	442
Role of SOD in protection against radiation-induced hippocampal dysfunction	443
Catalase reduces mitochondrial ROS for neuroprotection from proton irradiation.....	443
Neuroprotection in hypoxia-ischemia	444
Neuroprotection of the fetus and the neonate	444
Neuroprotection in preterm babies	444
Neuroprotection in neonatal hypoxic-ischemic brain injury	445
<i>Pathomechanism of neonatal hypoxic-ischemic brain injury</i>	445
<i>Management of neonatal hypoxia-ischemia</i>	445
<i>Approaches to neuroprotection in neonatal hypoxia-ischemia</i>	445
<i>Hyperbaric oxygen for neonatal hypoxia-ischemia</i>	446
<i>Hypothermia for neonatal hypoxia-ischemia</i>	446

<i>Melatonin for neonatal hypoxia-ischemia</i>	447
<i>Minocycline for neonatal hypoxia-ischemia</i>	447
<i>Nicotinamide mononucleotide adenylyl transferase 1</i>	447
<i>Nitric oxide inhalation for neonatal hypoxia-ischemia</i>	447
<i>Plasminogen activator inhibitor-1 for neonatal hypoxia-ischemia</i>	447
<i>Recombinant erythropoietin for neonatal hypoxia-ischemia</i>	448
Neuroprotection in carbon monoxide poisoning	448
Pathomechanism of CO poisoning as a basis for neuroprotection.....	448
Management of CO poisoning	449
Neuroprotection after cardiac arrest	450
Neuroprotection in delayed post-hypoxic leukoencephalopathy	450
Neuroprotection in sleep apnea	451
Neuroprotection in mitochondrial dysfunction	451
Mitochondrial permeability transition	452
Mitochondrial approaches for neuroprotection.....	452
Methylene blue	453
Role of nanolasers in evaluation of mitochondrial neuroprotectants	453
Neuroprotection in mitochondrial encephalopathies	454
Neuroprotection in psychiatric disorders	454
Cognitive impairment in schizophrenia.....	454
Electroconvulsive therapy and neuroprotection	455
Neuroprotection in schizophrenia	455
Neuroplasticity and neuroprotection in stress-induced psychiatric disorders.....	455
Neuroprotection in hearing loss	456
Causes of hearing loss.....	456
Pathomechanism of hearing loss	457
Prevention and treatment of hearing loss	457
<i>Hyperbaric oxygen for hearing loss</i>	458
<i>Stem cell therapy for hearing loss</i>	458
<i>Auditory hair cell replacement by gene therapy</i>	458
<i>Pharmaceutical approaches to hearing loss</i>	459
Neuroprotection of peripheral nerves	460
Neuroprotective agents for peripheral nerves	460
<i>Acetyl-L-carnitine for peripheral nerve injuries</i>	461
<i>Atorvastatin for peripheral nerve injuries</i>	461
<i>Erythropoietin for neuroprotection in peripheral nerve injuries</i>	461
Neuroprotection in peripheral nerve injuries	462
<i>Role of hyperbaric oxygen in peripheral nerve injuries</i>	462
<i>Role of neurotrophic factors in peripheral nerve injuries</i>	462
<i>Pharmacological approaches to Schwann cells</i>	462
<i>Role of gene therapy in neuroprotection of injured peripheral nerves</i>	462
<i>Schwann cell transplantation for peripheral nerve injury</i>	463
<i>Targeting Wallerian degeneration slow protein for neuroprotection</i>	463
Peripheral neuropathy	463
<i>Neuroprotection in diabetic neuropathy</i>	463
<i>Cell therapy for neuroprotection in diabetic neuropathy</i>	464
<i>Gene therapy with zinc finger DNA-binding proteins</i>	464
<i>Neuroprotection in chemotherapy-induced neuropathy</i>	464
Chronic inflammatory demyelinating polyradiculoneuropathy	465
<i>Neuroprotection in CIDP</i>	465
12. Neuroprotection of the Optic nerve and the Retina	467
Introduction	467
Optic neuropathy	467
Pathophysiology	467
Neuroprotection in optic neuritis	468
<i>Evaluating efficacy of drugs for optic neuritis</i>	469
<i>Flupirtine</i>	469
<i>Sodium channel blockers</i>	470
<i>Resveratrol</i>	470
Neuroprotection in optic nerve trauma	470
Potential regeneration of the optic nerve.....	471
Subthreshold transpupillary thermotherapy for protection of RGCs.....	471
Neuroprotection of optic nerve in glaucoma	471
Aminoguanidine as a neuroprotective in glaucoma	473
Antiglutamate agents for neuroprotection of optic nerve	473
Betaxolol	473
NGF eye drops.....	473
Targeting A β in glaucoma treatment.....	474
TNF- α blockers for neuroprotection in glaucoma	474
Concluding remarks about neuroprotection in glaucoma.....	474

Neuroprotection in retinal ischemia	474
β-adrenoceptor antagonists.....	475
Brimonidine as a neuroprotective is ischemic retinopathy.....	475
Endogenous neuroprotection in the retina.....	476
Erythropoietin for neuroprotection of retinal ischemia.....	476
Gene therapy for retinal neuroprotection.....	476
Hyperbaric oxygen for central retinal artery occlusion.....	477
Levodopa for treating non-arteritic anterior ischemic optic neuropathy.....	477
Thioredoxin as a neuroprotective agent in retinal ischemia.....	477
Protection against oxygen-induced retinopathy	477
Neuroprotection in macular degeneration	478
Epidemiology.....	478
Pathomechanism of AMD.....	478
Current treatment of AMD.....	478
Novel neuroprotective strategies against retinal degeneration.....	480
Antiangiogenic agents.....	481
Humanized MAb against Aβ.....	481
LXR agonists.....	482
Neurotrophic factors for neuroprotection in AMD.....	482
<i>CNTF for neuroprotection in AMD</i>	482
<i>N-acetylserotonin derivatives</i>	482
Nutritional protection against AMD.....	482
Progestogenic hormones.....	483
Protection of retinal cells from oxidative-stress-induced apoptosis.....	483
Sulindac.....	483
Tandospirone.....	484
Cell therapy for macular degeneration.....	484
<i>Retinal pigment epithelial cells</i>	484
<i>Stem cells</i>	484
<i>Neural progenitor cells</i>	484
Gene therapy for retinal degeneration.....	485
RNAi-based treatments for AMD.....	485
Neuroprotection in proliferative diabetic retinopathy	486
RNAi-based approaches to diabetic retinopathy.....	486
Clinical trials for optic nerve and retinal neuroprotection	487
13. Neuroprotection during Anesthesia and Surgery	489
Introduction	489
Anesthetic agents as neuroprotectives	489
Barbiturates.....	489
<i>Thiopental</i>	490
Etomidate.....	491
Propofol.....	491
Ketamine.....	491
Gaseous anesthetics.....	492
<i>Isoflurane</i>	492
<i>Xenon</i>	492
Local anesthetics.....	493
Monitoring of CNS function during anesthesia and surgery	493
Monitoring of cerebral function.....	493
Monitoring of spinal cord function during spinal surgery.....	493
Perioperative neuroprotection	494
Neuroprotection during cardiovascular procedures	495
CNS complications of cardiac surgery.....	495
Neuroprotective strategies during cardiac surgery.....	496
<i>Neuroprotection before anticipated or induced cardiac arrest</i>	497
<i>Neuroprotection during coronary artery bypass grafting</i>	497
<i>Preconditioning with hyperbaric oxygen</i>	498
<i>Neuroprotection in aortic surgery</i>	498
<i>Pharmacologic strategies for neuroprotection in aortic surgery</i>	499
Cerebral protection during organ transplantation surgery	499
Cerebral protection during neurosurgery	500
Cerebral angiography and endovascular surgery.....	500
Cerebral protection during surgery for arteriovenous malformations.....	500
Cerebral protection during surgery of intracranial aneurysms.....	500
Management of subarachnoid hemorrhage.....	501
<i>Vasospasm associated with subarachnoid hemorrhage</i>	501
Cerebral protection during carotid endarterectomy.....	503
Cerebral protection during surgery of brain tumors.....	503
Neuroprotective measures prior to surgery.....	504
<i>HBO preconditioning for neuroprotection during surgery</i>	504

Neuroprotection following surgery	504
<i>Neuroprotection by cranioplasty after decompressive craniectomy</i>	505
14. Markets for Neuroprotective Therapies.....	507
Introduction	507
The financial burden of CNS damage	507
Markets for neuroprotective therapies.....	507
Markets according to therapeutic areas.....	507
<i>Stroke</i>	508
<i>CNS injury</i>	508
<i>Alzheimer disease</i>	509
<i>Parkinson disease</i>	509
<i>Multiple sclerosis</i>	509
<i>Epilepsy</i>	509
Values of neuroprotective therapies in major world markets.....	509
Unmet needs in neuroprotectives	510
Future of neuroprotective therapies	511
Challenges in neuroprotective drug development	511
Promising areas of research in neuroprotection.....	512
<i>Autoreactive antibodies</i>	512
<i>Biological therapies for neuroprotection</i>	512
<i>Multidisciplinary approaches to neuroprotection</i>	513
15. References.....	515

Tables

Table 1-1: Historical landmarks in the development of neuroprotection	31
Table 1-2: Intrinsic neuroprotective factors.....	36
Table 1-3: Common features of pathophysiology of brain damage in diseases	44
Table 1-4: Place of neuroprotection in management of CNS disorders	45
Table 1-5: Indications for the use of neuroprotection	45
Table 1-6: Neuroprotective nanoparticles.....	51
Table 2-1: A classification of neuroprotective agents	55
Table 2-2: The neuroprotective effect of antiepileptic drugs	64
Table 2-3: Neuroprotective affect of minocycline in animal models.....	69
Table 2-4: Classification of antioxidants or free radical scavengers with neuroprotective potential.....	77
Table 2-5: Role of erythropoietin in the nervous system	82
Table 2-6: Ionotropic glutamate receptors	88
Table 2-7: Classification of metabotropic glutamate receptors (mGluRs)	88
Table 2-8: Methods for neuroprotection based on nonpharmacological preconditioning	140
Table 3-1: Cerebrovascular diseases that are relevant to neuroprotection.....	143
Table 3-2: Neuroprotective strategies for stroke	153
Table 3-3: Selected effective combinations of hypothermia with other neuroprotective strategies for the treatment of ischemic stroke in experimental models	185
Table 3-4: Neuroprotective gene transfer in models of cerebral ischemia	191
Table 3-5: Neuroprotective gene therapy in animal stroke models	191
Table 3-6: Neuroprotective agents in clinical development for acute cerebrovascular disease	194
Table 3-7: Some failed trials for neuroprotective therapy for stroke	197
Table 3-8: Preclinical assessment of neuroprotective agents in acute stroke models.....	206
Table 4-1: Classification of closed TBI	211
Table 4-2: Current conventional management of traumatic brain injury	220
Table 4-3: Neuroprotective strategies for traumatic brain injury	222
Table 4-4: Intrinsic factors that influence regeneration in the central nervous system	240
Table 4-5: A classification of approaches to regeneration of the brain following injury	241
Table 4-6: Ongoing or completed clinical trials for neuroprotection in TBI	243
Table 4-7: Discontinued or failed clinical trials for neuroprotection in TBI.....	244
Table 5-1: Secondary mechanisms in spinal cord injury	249
Table 5-2: Neuroprotective and regenerative approaches for SCI.....	250
Table 5-3: Clinical trials for neuroprotection in SCI	265
Table 6-1: Neurodegenerative disorders with dementia	275
Table 6-2: Drugs in clinical trials for spinal muscular atrophy	281
Table 6-3: Approaches to neuroprotection in CJD.....	283
Table 6-4: Glutamate-based therapies in clinical development for neurodegenerative disorders	285
Table 7-1: Prevalence of Parkinson's disease in major markets 2016-2026	287
Table 7-2: Factors in the etiology of Parkinson's disease.....	287
Table 7-3: Strategies for the treatment of Parkinson's disease	295
Table 7-4: Gene therapy techniques applicable to Parkinson disease	308
Table 7-5: Current clinical trials of neuroprotective therapies for Parkinson disease	320

Table 7-6: Failed clinical trials of neuroprotective therapies for Parkinson disease.....	321
Table 7-7: Evaluation of neuroprotective agents for PD	322
Table 8-1: Cholinergic approaches to the treatment of Alzheimer's disease	327
Table 8-2: Neuroprotective agents for Alzheimer's disease.....	327
Table 8-3: Clinical trials for neuroprotection in Alzheimer disease	340
Table 8-4: Discontinued, failed or inconclusive clinical trials of Alzheimer disease	346
Table 8-5: Strategies for discovery of neuroprotective therapies for AD	349
Table 9-1: Neuroprotective approaches in HD.....	355
Table 10-1: Hypotheses for the pathogenesis of amyotrophic lateral sclerosis	367
Table 10-2: Genetic diagnostic biomarkers of ALS.....	370
Table 10-3: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	372
Table 10-4: Clinical trials of neuroprotective therapies for ALS	386
Table 10-5: Failed or discontinued trials of neuroprotective therapies for ALS.....	387
Table 11-1: Therapeutic approaches to subcortical vascular dementia	396
Table 11-2: Pharmacological neuroprotection against the sequelae of seizures	401
Table 11-3: Neuroprotective effect of AEDs in animal models of status epilepticus (SE)	402
Table 11-4: Specific therapies for MS based on postulated pathomechanisms.....	408
Table 11-5: Approved neuroprotective therapies for multiple sclerosis.....	409
Table 11-6: Neuroprotective therapies for multiple sclerosis in clinical trials	410
Table 11-7: Measures to prevent acute bilirubin encephalopathy	439
Table 11-8: Approaches to neuroprotection in neonatal hypoxia-ischemia.....	446
Table 11-9: Drugs with neuroprotective effect at mitochondrial level.....	452
Table 11-10: Causes of sensorineural hearing impairment	456
Table 11-11: Strategies for prevention and treatment of sensorineural hearing loss.....	457
Table 11-12: Agents for neuroprotection of the peripheral nervous system	460
Table 12-1: Causes of optic neuropathy.....	467
Table 12-2: Clinical trials of neuroprotective therapies in optic neuritis.....	469
Table 12-3: Neuroprotection of the optic nerve in glaucoma.....	472
Table 12-4: Strategies for neuroprotection in retinal ischemia	475
Table 12-5: Novel neuroprotective strategies against retinal degeneration	480
Table 12-6: Clinical trials for retinal neuroprotection	487
Table 13-1: CNS complications associated with cardiac procedures	495
Table 13-2: Strategies for protection of the brain during cardiac surgery	496
Table 13-3: Medical and surgical methods of cerebral vasospasm management.....	502
Table 13-4: Neuroprotection by prevention of vasospasm.....	502
Table 14-1: Neuroprotective market values 2016-2026	508
Table 14-2: Values of neuroprotective therapies in major world markets from 2016-26	509

Figures

Figure 2-1: Mechanism of neuroprotective effect of sigma-1 receptor agonists	63
Figure 2-2: NMDA receptor ion channel complex.....	92
Figure 2-3: Neuroprotective effect of galantamine	114
Figure 3-1: Some steps in the ischemic cascade and site of action of neuroprotectives	144
Figure 3-2: Relationship between dementia and acute ischemic stroke	152
Figure 3-3: A roadmap for neuroprotection	207
Figure 4-1: Cascade of events following traumatic brain injury	213
Figure 4-2: Neurometabolic cascade of mild TBI	214
Figure 4-3: Secondary injury mechanisms after TBI	215
Figure 4-4: Management of raised ICP after TBI	221
Figure 5-1: Pathomechanism of acute spinal cord injury	248
Figure 7-1: Neuroprotective strategies against death of dopamine-containing neurons in PD	293
Figure 9-1: Role of HTT protein in pathogenesis of HD and points of intervention.....	362
Figure 9-2: Antisense therapeutic approaches to HD for lowering huntingtin	366
Figure 11-1: A schematic overview of synaptopathies.....	391
Figure 11-2: Common mechanisms of neural damage in cerebral ischemia and seizures.....	399
Figure 11-3: Role of neuroprotection in epilepsy and its treatment.....	401
Figure 11-4: Mechanisms of neonatal hypoxia-ischemia and targets for neuroprotection.....	445
Figure 14-1: Unmet therapeutic needs in neuroprotective therapies	511